Fatty acid clues: could Mom's placenta hold key to preemie eye disease?

NCT ID NCT04819893

Recruiting now Knowledge-focused Sponsor: Centre Hospitalier Universitaire Dijon Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at why some premature babies develop retinopathy of prematurity (ROP), an eye condition that can affect vision. Researchers think fatty acids from the mother may play a role. They will collect blood, placenta, and cord samples from 135 mothers and their preterm or full-term babies to see how fatty acid receptors in the placenta relate to ROP. The goal is to better understand the biology, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this research could point toward ways to prevent or better manage retinopathy of prematurity by understanding how fatty acids are transferred from mother to baby.
What could go wrong: This is an observational study focused on understanding mechanisms, not testing a treatment. It is small (135 participants) and early-stage, so results may not lead directly to clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREMATURITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Premature Birth retinal disorder retinopathy of prematurity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PREMATURITY RETINOPATHY

Contacts and locations

Locations

Chu Dijon Bourogne
RECRUITING

Dijon, 21000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.